Evaluation of Safety and Pharmacokinetics of BDT272 in Single and Multiple Ascending Doses in Healthy Volunteers with Moderate to Severe Pain

The primary objective of this study is to evaluate the **safety** and **pharmacokinetics** of BDT272 following the administration of single and increasing doses in healthy volunteers. This is clinically relevant as it aims to establish the safety profile and absorption, distribution, metabolism, and excretion characteristics of BDT272, which is intended for the management of moderate to severe pain. Understanding these parameters is crucial for determining the appropriate dosing regimen and ensuring patient safety in future clinical applications.

The clinical trial is designed to evaluate interventions for individuals experiencing **moderate to severe pain**. The study population includes both male and female participants, with an age range categorized as adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants involved in the study. Selection criteria and lifestyle considerations such as diet, physical activity, or habits have not been detailed in the available data. The absence of specific inclusion or exclusion criteria suggests a broad approach to participant selection, although further details are not disclosed by the sponsor.

The clinical trial is designed to evaluate the **safety** and pharmacokinetics of BDT272 in healthy volunteers. This is a Phase 1 trial, which will involve the first administration of single and increasing doses of the investigational product. The study is structured as a randomized, double-blind, and controlled trial, ensuring that neither the participants nor the researchers know who is receiving the active treatment or the placebo, thus minimizing bias. The trial is set to commence recruitment on November 1, 2024, and is expected to conclude by November 1, 2025, with the total duration of the trial being approximately one year.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria will be assessed. This visit will determine if the potential participants meet the necessary conditions to partake in the study. Following successful screening, participants will be enrolled and will attend multiple follow-up visits, which are scheduled to monitor the safety and pharmacokinetic parameters of BDT272. These visits will include various assessments and data collection to ensure the ongoing safety of the participants and to gather necessary pharmacokinetic data. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to ensure the well-being of the participants and to collect any remaining data required for the study's objectives.

The expected length of participant involvement will vary depending on the dosing schedule and the number of follow-up visits required. However, participants should anticipate being involved for the duration of the trial, unless conditions arise that necessitate early termination. Such conditions may include adverse reactions to the investigational product, non-compliance with study procedures, or withdrawal of consent by the participant. The trial is focused on assessing the investigational product's impact on **moderate to severe pain**, although the participants themselves will be healthy volunteers. The study's design and procedures are meticulously planned to ensure the collection of high-quality data while maintaining the safety and rights of the participants throughout the trial.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements cannot be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not present in the provided data. As such, these aspects cannot be detailed in the current context.

No specific details regarding the assessment of efficacy in the clinical trial are provided in the available data. Information on parameters or endpoints, methods, schedule for measuring, collecting, and analyzing efficacy parameters, as well as tools or instruments involved in efficacy assessments, is not included. The trial is identified as a Phase 1 study, with an estimated recruitment start date of November 1, 2024, and an estimated end date of November 1, 2025. Further details on efficacy assessment are not available in the provided source material.